Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accomplish, acoustic, administered, adult, alongside, analogy, Anchor, Arabia, Argentina, Asian, assumption, augment, begun, belief, BioCardia, Biotech, bland, Blue, bond, Breakthrough, BSC, budget, carboxypeptidase, carcinoma, catastrophic, Center, Cerene, Chile, Chinese, cholangiopancreatography, Colombia, Columbia, complementary, condensed, confirmed, congressional, consequential, CroFab, cryotherapy, curve, cybersecurity, Czech, database, deadline, Decompression, Dialogue, DigiFab, digoxin, DIRECTSENSE, divided, dose, duodenoscope, Eastern, electrode, empower, empowering, ERCP, escalate, escalation, EXALT, excretion, Fab, factually, Fenner, Fountain, GDPR, globe, GMP, guideline, HCC, Hemoclip, hepatocellular, HMO, IM, ImageReady, Immune, implicit, indemnify, Indonesia, Inflation, Inline, Instinct, inventorship, IPR, Janssen, Jonathan, kit, Korean, land, Linkbase, literature, Los, Louisiana, LSS, lumbar, Lynch, MDD, median, Merrill, methotrexate, micromole, microsphere, misleading, Mississippi, Monson, Municipal, necessarily, North, Nova, obsolescence, occurrence, online, oral, OrionTM, outreach, overdose, overexposure, Ovine, pancreaticobiliary, physical, physiology, Pierce, pit, plasma, POLARx, presidential, prevalence, Prosthetic, proud, proven, QSF, quantity, radioactive, Red, renal, renminbi, Republic, residual, Retail, retention, retrograde, RPI, SAB, Saudi, Schema, Scotia, scrap, secret, Securityholder, Shave, Sherman, Shield, Slovakia, slower, Smith, Solyx, space, specialist, specialty, stability, Superion, supersede, Taiwan, Taxonomy, testimony, Thailand, Therasphere, tool, toxic, toxicity, Turkey, UDAAN, unaudited, uncapped, underrepresented, undisclosed, unfunded, unremitted, Valley, Varian, Vertiflex, Vietnam, viper, vital, volunteered, Voraxaze, warehouse, weaker, Wear, withdrew, won, worker, XBRL, zytiga
Removed:
aforementioned, Alpharetta, apportionment, aware, brand, bringing, capable, cell, circumstance, clarification, comparability, conducting, consultant, decided, deficiency, disclosing, distributor, doctrine, Dr, EEA, endochoice, enforced, expended, factor, finalized, flat, Georgia, Greece, hdx, inactive, ineffective, intervention, Jang, jury, Lesh, literal, literally, lost, Maria, Markman, nonprofit, Orion, oversee, pathology, payor, Portugal, Quincy, remanded, reorganization, rescission, responding, rolled, scrutinizing, SpA, Spain, stipulation, today, unreduced, updating, vacated, warfarin, wholly
Filing tables
Filing exhibits
- 10-K Annual report
- 4.2 Exhibit 4.2 - Description of Registered Securities FY2019
- 21 Exhibit 21 - FY2019 List of Subsidiaries Dated Jan 30, 2020
- 23 Exhibit 23 - E&y Consent FY2019
- 31.1 Exhibit 31.1 CEO 302 Cert FY2019
- 31.2 Exhibit 31.2 CFO 302 Cert FY2019
- 32.1 Exhibit 32.1 CEO 906 Cert FY2019
- 32.2 Exhibit 32.2 CFO 906 Cert FY2019
- Download Excel data file
- View Excel data file
Related press release
Associated BSX transcripts
BSX similar filings
Filing view
External links
EXHIBIT 23
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-3 Nos. 333-223095, 333-76346, 333-61994, and 333-64991) of Boston Scientific Corporation, |
(2) | Registration Statement (Form S-4 Nos. 333-22581 and 333-131608) of Boston Scientific Corporation, and |
(3) | Registration Statement (Form S-8 Nos. 333-25033, 333-25037, 333-36636, 333-61056, 333-61060, 333-76380, 333-98755, 333-111047, 333-131608, 333-133569, 333-134932, 333-151280, 333-174620, 333-174622, 333-188905, and 333-196672) pertaining to the Employees' Savings Plan of Boston Scientific Corporation; |
of our reports dated February 25, 2020, with respect to the consolidated financial statements and schedule of Boston Scientific Corporation and the effectiveness of internal control over financial reporting of Boston Scientific Corporation included in this Annual Report (Form 10-K) of Boston Scientific Corporation for the year ended December 31, 2019.
/s/ Ernst & Young LLP
Boston, Massachusetts
February 25, 2020